SUPPORT LINE
0300 111 1234
Read here the history of Tolvaptan.
To access the latest papers published on Tolvaptan, please visit PubMed website. (The search terms used to show this page of results were 'tolvaptan' AND 'polycystic kidney disease'.)
User Rating: 3 / 5
The European Medicines Agency (EMA) has recommended granting a marketing authorisation to tolvaptan, which now has the brand name: JINARC.
User Rating: 1 / 5
Listen to Dr Donal O'Donoghue, the former National Clinical Director of Kidney Care in England, discuss the Tolvaptan trial and its implications for ADPKD patients. (20 minute video skype chat.)
User Rating: 3 / 5
The Department of Health has asked NICE - the National Institute for Health and Care Excellence - to conduct an appraisal of tolvaptan for treating ADPKD (autosomal dominant polycystic kidney disease). The date of the appraisal meeting will be 1st April 2015.
User Rating: 1 / 5
At the American Society of Nephrology (ASN) meeting on 3 November 2012, Dr Vicente Torrres from the Mayo Clinic, together with research collaborators, reported the results of a 3 year global study known as TEMPO - Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease Outcomes.
RT @SqueakyGem: @AmandaPichini @PKDCharity @J9_Austin Hope this is introduced in my area, I struggle with feelings about my hereditary cond…
RT @Genomethics: Films (free) for patients that explain genomics, can be used in genetic counselling, on websites for publics, anywhere whe…
RT @AmandaPichini: Fantastic first UK pilot of psychiatric #geneticcounseling: benefits include empowerment, and the space to discuss guilt…
Can anyone help with this request? #organdonation https://t.co/Aj5M2HtiMS
@actiononsalt Survey exposes the salads that pose a serious hidden salty threat to our health. #toomuchsalt… https://t.co/zj0WDkLk85
RT @SqueakyGem: @AmandaPichini @PKDCharity @J9_Austin Hope this is introduced in my area, I struggle with feelings about my hereditary cond…
